Advanced Therapeutic Applications of Camel Milk in Gastrointestinal Pathology: Microbiome Modulation, Mucosal Regeneration, and the Critical Role of Processing Technologies

Author:

Adrian Wadowski

Lead Researcher, CamelWay | Independent Researcher

Specialized Nutritional Science & Functional Dairy

Email: adivv@adivv.pl | Web: adivv.pl

ORCID: 0009-0005-3393-7953

Abstract:

This report synthesizes multi-omic data from 2024–2026 investigations regarding the efficacy of camel milk in treating Ulcerative Colitis (UC) and Irritable Bowel Syndrome (IBS). It highlights the epigenetic role of exosomal miR-148a-3p in suppressing NF-κB signaling and the mandatory requirement for Low-Temperature Spray Drying (LTSD) to preserve bioactivity.

Keywords: *Camel Milk, Exosomes, miR-148a-3p, Ulcerative Colitis, Microbiome Modulation, Low-Temperature Spray Drying, Gut-Brain Axis.*

Gastrointestinal Pathology and the Intestinal Barrier

The global incidence of chronic gastrointestinal disorders, most notably Inflammatory Bowel Disease (IBD) - which encompasses Ulcerative Colitis (UC) and Crohn’s disease - along with Irritable Bowel Syndrome (IBS) and intestinal hyperpermeability, represents a profound and escalating challenge in modern gastroenterology and clinical immunology. The complex pathophysiology of these conditions is intricately linked to a self-perpetuating triad of molecular and cellular dysfunctions: severe dysbiosis of the commensal gut microbiota, chronic hyperactivation of mucosal innate and adaptive immune responses, and the profound, persistent degradation of the intestinal epithelial barrier. The intestinal epithelium functions not merely as a passive biological sieve for nutrient absorption but as a highly

dynamic, critical interface that provides a formidable physical and immunological defense against luminal antigens, endotoxins, and opportunistic or pathogenic microorganisms.

The structural integrity of this barrier relies on a highly regulated, complex network of tight junction proteins (TJPs), primarily comprising Zonula Occludens-1 (ZO-1), occludin, and claudin-1, which act in concert with the dense glycoprotein mucin layer (such as MUC2) secreted continuously by specialized goblet cells within the colonic crypts. When severe environmental stressors, sustained pathogenic overgrowth, chemical insults, or specific genetic predispositions trigger the breakdown of these tight junctions, the architectural integrity of the gut fails. This failure allows luminal lipopolysaccharides (LPS) from Gram-negative bacteria and un-digested, highly antigenic dietary proteins to translocate across the paracellular space and into the systemic circulation, a phenomenon clinically recognized as "leaky gut" syndrome.

This uncontrolled paracellular leakage immediately triggers a robust and often disproportionate immune cascade. The translocated antigens prompt the activation of pattern recognition receptors, particularly Toll-like receptor 4 (TLR4), located on the surfaces of resident mucosal macrophages and dendritic cells. The downstream effect of this receptor activation is the swift initiation of the NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) signaling pathway. The persistent, unchecked activation and nuclear translocation of NF-κB result in the continuous, high-volume transcription of potent pro-inflammatory cytokines, notably tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β). This locks the host into a devastating cycle of chronic colonic inflammation, oxidative stress, and progressive tissue destruction.

In the contemporary search for efficacious, long-term interventions, the clinical paradigm is rapidly shifting toward functional nutrition, orthomolecular medicine, and microbiome-targeted therapeutics. Conventional pharmacological therapies for IBD and severe IBS, which heavily utilize systemic corticosteroids, broad-spectrum immunosuppressants, and targeted biologics, often present substantial adverse effects, prohibitive long-term costs, and diminishing therapeutic returns over extended periods of administration. Furthermore, these traditional therapies frequently fail to address the root dysbiosis or actively repair the mucosal barrier, focusing instead on merely suppressing the downstream

inflammatory symptoms. Consequently, targeted nutritional interventions utilizing biologically active, naturally occurring macro- and micro-molecules have emerged as a primary focus of advanced gastroenterological research.

Among these emerging natural therapeutics, camel milk (harvested from *Camelus dromedarius* and *Camelus bactrianus*) has been isolated and validated as a remarkably potent, multifaceted therapeutic agent. Unlike bovine, caprine, or ovine milks, camel milk possesses a highly divergent, evolutionarily specialized biochemical profile. It is entirely devoid of the highly allergenic β-lactoglobulin protein, while simultaneously harboring exceptionally high concentrations of unique immunoglobulins, native lactoferrin, and exosomal microRNAs capable of enacting direct epigenetic regulation within the human gastrointestinal tract.

Recent comprehensive clinical and multi-omic investigations published throughout 2024 and 2025 have meticulously mapped the precise, multi-pathway molecular mechanisms by which camel milk exerts its regenerative effects on the damaged gastrointestinal tract. These elucidated mechanisms range from the fundamental restoration of the gut microbiota-short-chain fatty acid (SCFA) axis to the epigenetic suppression of colonic apoptosis and inflammation via the exosomal delivery of microRNAs. However, the translational clinical success of these therapies is entirely dependent upon the structural preservation of these delicate biomolecules during industrial manufacturing. Extensive bio-analytical research increasingly demonstrates that the industrial processing and dehydration methods applied to camel milk definitively dictate its clinical efficacy, highlighting a critical intersection between advanced food science engineering and targeted therapeutic outcomes.

The Biochemical Architecture of Camel Milk Bioactives

To comprehensively understand the profound therapeutic efficacy of camel milk in treating mucosal damage, modulating the microbiome, and managing inflammatory bowel diseases, a rigorous analysis of its specialized biochemical architecture is required. Camel milk cannot be classified merely as a source of mammalian macronutrients; it is a highly complex, evolutionary biological fluid designed to impart robust passive immunity, facilitate rapid cellular development, and maintain physiological

homeostasis under conditions of extreme environmental stress, dehydration, and high ambient temperatures.

Lactoferrin (Lf) and Lysozyme Dynamics

Lactoferrin is a highly pleiotropic, 80 kDa iron-binding glycoprotein belonging to the transferrin family. It is found in camel milk at concentrations that significantly eclipse those observed in standard bovine milk. Comparative biochemical analyses indicate that camel lactoferrin can reach extraordinary concentrations of up to 5.10 mg/mL in early lactation colostrum, remaining substantially elevated even in mature, late-stage milk, whereas bovine equivalents typically hover around 0.50 mg/mL.

The therapeutic value of camel lactoferrin in the context of gastrointestinal pathology lies in its sophisticated, tri-fold mechanism of action: aggressive iron chelation, direct microbial membrane disruption, and profound immune modulation. By tightly binding free ferric iron (Fe^{3+}) in the intestinal lumen, lactoferrin effectively deprives rapidly dividing pathogenic bacteria (such as pathogenic strains of *Escherichia coli*, *Salmonella*, and various *Pseudomonas* species) of the crucial micronutrients required for their cellular respiration and replication. This metabolic starvation exerts a potent, broad-spectrum bacteriostatic effect without disrupting the broader ecosystem.

Simultaneously, lactoferrin acts as a highly effective, selective prebiotic. It actively promotes the proliferation of beneficial indigenous taxa, such as *Bifidobacterium* and *Lactobacillus* species, which have evolved unique, alternative iron-acquisition mechanisms or have remarkably low iron requirements, allowing them to thrive in the low-iron environment engineered by the lactoferrin. Furthermore, camel lactoferrin demonstrates a remarkable structural resistance to proteolytic cleavage by gastric pepsin and low pH. This structural resilience allows a significant proportion of the intact glycoprotein to bypass gastric digestion and reach the lower intestine and colon, where it directly interacts with specific epithelial receptors to suppress the transcription and subsequent production of pro-inflammatory cytokines, thus calming the mucosal immune response directly at the site of IBD-related inflammation.

Heavy-Chain Immunoglobulins (IgG) and VHH Nanobodies

The immunoglobulin profile of camel milk is exceptionally unique in the mammalian kingdom and is the subject of intense pharmacological research. While camel milk contains standard heterotetrameric Immunoglobulin G (IgG) which provides robust, broad-spectrum passive immunity to the host, camelids possess the unique biological capacity to synthesize a distinct class of antibodies known as heavy-chain-only antibodies (HCAbs). The antigen-binding domain of these HCAbs is not distributed across multiple protein chains; rather, it consists of a single, highly stable variable domain, scientifically termed VHH or, more commonly in therapeutic literature, "nanobodies".

Nanobodies possess a molecular weight of merely ~15 kDa and measure approximately 4 nm in length by 2.5 nm in width. This represents a structural footprint that is less than one-tenth the size of conventional human or bovine antibodies. This microscopic dimension endows camel milk nanobodies with unprecedented pharmacological and pharmacokinetic advantages, particularly for oral administration. Conventional monoclonal and polyclonal antibodies are rapidly and irreversibly degraded by the harsh, highly acidic, and protease-rich environment of the human gastrointestinal tract, rendering oral antibody therapies largely ineffective.

In stark contrast, the rigid physical structure of camelid nanobodies, heavily reinforced by the frequent presence of an extra stabilizing disulfide bond within their complementarity-determining regions (CDRs), confers exceptional, unparalleled resistance to high heat, extreme pH variations (both highly acidic and alkaline), and aggressive gastrointestinal proteases like trypsin and chymotrypsin. Once they safely transit into the inflamed intestine, their nanoscale size allows them to achieve deep, rapid tissue penetration. They easily navigate through the dense, protective colonic mucin layer to bind directly and tightly to cryptic, otherwise inaccessible antigens on the surface of inflamed intestinal epithelial cells, as well as binding specifically to localized mucosal pathogens. Recent advanced bioengineering of these naturally occurring VHH antibodies has definitively demonstrated their capacity to serve as highly potent oral biologics. For instance, specific VHH formulations have been documented successfully inhibiting inflammatory targets such as the Interleukin-23 receptor (IL-23R) deep within the inflamed colonic tissue of induced IBD models, halting the inflammatory cascade at its source.

Insulin-Like Peptides and Systemic Metabolic Crosstalk

Beyond the localized repair of the gut mucosa, camel milk exerts a heavy, well-documented influence on systemic metabolic health, a factor that is fundamentally linked to the stability of the microbiome. Camel milk contains highly active insulin-like proteins, found at an impressive concentration of approximately 52 units per liter, which are naturally encapsulated within protective lipid vesicles. This unique lipid encapsulation acts as an advanced, evolutionary delivery mechanism, effectively shielding the delicate insulin-like peptides from enzymatic and acidic degradation in the stomach, thereby facilitating their intact absorption into the systemic bloodstream via the highly vascularized small intestine.

Extensive clinical research led by nutritional science teams demonstrates that the strategic integration of camel milk into daily therapeutic protocols significantly lowers fasting blood glucose levels, improves long-term HbA1c metrics, and effectively mitigates systemic dyslipidemia. These lipid profile improvements are characterized by the significant lowering of Total Cholesterol (TC), low-density lipoprotein (LDL), and triglycerides (TG), alongside a simultaneous elevation of high-density lipoprotein (HDL) in patient populations suffering from both Type 1 and Type 2 Diabetes mellitus.

The relevance of this metabolic regulation to gastrointestinal health cannot be overstated. Chronic systemic hyperglycemia and unchecked insulin resistance are known to severely exacerbate intestinal epithelial permeability, fuel systemic low-grade inflammation, and drive severe gut dysbiosis. Therefore, the stabilization of core metabolic markers via the ingestion of these camel milk-derived insulin-like peptides serves as a vital, secondary therapeutic mechanism in comprehensively resolving "leaky gut" syndrome and restoring systemic metabolic and immunological homeostasis.

Bioactive Component	Structural/Physical Characteristic	Primary Gastrointestinal Mechanism of Action	Clinical / Pathological Impact
Lactoferrin (Lf)	80 kDa iron-binding glycoprotein; highly protease-resistant.	Active iron chelation depriving pathogens of nutrients; binds epithelial receptors to suppress cytokines.	Halts pathogen replication; resolves localized mucosal inflammation and oxidative stress.
VHH Nanobodies	~15 kDa single-domain antibody; possesses extra stabilizing disulfide bonds.	Deep tissue penetration through mucin; highly stable in harsh gastric pH and protease environments.	Directly neutralizes cryptic mucosal antigens and toxins; blocks specific inflammatory receptors (e.g., IL-23R).
Insulin-Like Peptides	52 U/L concentration; heavily encapsulated in robust lipid vesicles.	Bypasses gastric degradation; absorbed intact to interact directly with systemic insulin receptors.	Lowers fasting glucose; mitigates hyper-permeability caused by chronic hyperglycemia and metabolic syndrome.
Exosomes (CM-EVs)	30–200 nm lipid bilayer vesicles containing microRNAs (e.g., miR-148a-3p).	Endocytosed by host colonocytes; enacts direct intracellular epigenetic regulation of host DNA.	Upregulates SIRT1; completely suppresses NF-κB inflammatory signaling; repairs TJP structure.

Technological Bottlenecks in Production: The Imperative of Low-Temperature Spray Drying (LTSD)

The complex quaternary and tertiary folding structures of lactoferrin, immunoglobulin G, and the singular VHH nanobodies render them exceptionally susceptible to rapid, irreversible denaturation during commercial dairy processing. Consequently, the profound therapeutic applications of camel milk outlined above are strictly gated by the industrial methodology utilized to convert raw liquid desert milk into a shelf-stable, globally distributable dry powder. Standard global dairy industry practices primarily rely on either high-temperature spray drying or freeze-drying (lyophilization), both

of which present critical, therapy-defeating flaws when handling highly sensitive, therapeutic-grade camel milk.

Leading institutional voices in the clinical application of alternative functional dairy, operating out of specialized nutritional science divisions (such as those maintained by Adrian Wadowski and the research frameworks detailed at CamelWay Camel Milk Research Hub [Science Section]), have extensively documented the absolute necessity of specialized, low-thermal processing to maintain the efficacy of the "Gut-Skin" and "Gut-Brain" axes. Comprehensive research and product development protocols highlight that the biological efficacy of camel milk in treating severe metabolic disorders, autoimmune conditions (such as severe eczema and psoriasis), and supporting neurodiversity (specifically Autism spectrum therapies utilizing rigorous GFCF - Gluten-Free, Casein-Free diets) is entirely, inextricably contingent upon the flawless structural preservation of these delicate proteins.

The Physiological Failure of High-Temperature and Freeze-Drying Methodologies

Standard high-temperature spray drying, typically utilized for bovine milk and whey commodities, utilizes brutal inlet temperatures frequently exceeding 180°C and outlet temperatures remaining above 90°C. At these extreme thermal parameters, the kinetic and thermodynamic stress induces the rapid, violent unfolding of the lactoferrin tertiary structure, irreversibly destroying its functional iron-binding clefts and utterly eliminating its bacteriostatic efficacy. Furthermore, this extreme thermal exposure leads to the complete denaturation of IgG, destroying its delicate antigen-recognition capabilities. It simultaneously induces the aggressive Maillard reaction (the non-enzymatic browning between amino acids and reducing sugars), which permanently diminishes the bioavailability of essential amino acids, damages the peptide integrity, and drastically alters the organoleptic profile, leaving the powder with a distinctly burnt, cooked, or caramelized taste.

Conversely, the alternative of freeze-drying (lyophilization) entirely avoids heat but introduces a set of distinct, equally detrimental physical and mechanical limitations. Freeze-drying relies on sublimation under deep vacuum, which creates a highly porous, irregular, sheet-like particle morphology (often appearing as jagged flakes under microscopy). These flakes are incredibly hygroscopic and exhibit

notoriously poor flowability during industrial handling and packaging. From a strict clinical and end-user standpoint, freeze-dried camel milk clumps severely upon hydration, aggressively resists smooth reconstitution in water, and frequently undergoes rapid, devastating lipid oxidation. This oxidation occurs because the highly porous surface area exposes the milk fats to residual environmental oxygen over time, resulting in a distinctly chalky, rancid, and oxidized taste. Moreover, the freezing process itself can cause severe cryodamage, rupturing extracellular vesicles and shattering specific protein structures if complex, artificial lyoprotectants are not heavily utilized during the process.

The Low-Temperature Spray Drying (LTSD) Paradigm Advantage

To successfully bridge the massive gap between microbiological safety, total bioactive preservation, and physical consumer convenience, advanced Low-Temperature Spray Drying (LTSD) has been firmly established as the absolute gold standard for therapeutic camel milk production. This state-of-the-art technology operates under significantly modified and strictly controlled thermodynamic parameters, frequently utilizing heavily dehumidified air to artificially increase the driving force for rapid water evaporation without ever requiring the application of excessive heat. Inlet air temperatures are strictly governed (often maintained between a gentle 80°C and 125°C), while the critical outlet temperatures - which dictate the actual thermal stress experienced by the drying particle - are maintained safely below the strict protein denaturation threshold (typically tightly controlled between 50°C to 70°C).

Rigorous physical testing, including Fluorescence and Far-UV Circular Dichroism analyses, definitively confirm that LTSD processing ensures minimal to zero unfolding of the delicate lactoferrin structure, reliably retaining >99% of its native, functional structural integrity. The precise LTSD process atomizes the liquid camel milk into perfectly uniform, microscopic droplets. As the water evaporates rapidly but gently from the droplet surface at these controlled low temperatures, it leaves behind perfectly spherical, closed, and free-flowing solid microspheres. These distinct microspheres possess mathematically ideal surface-to-volume ratios, allowing the final powder to dissolve instantly and entirely seamlessly in liquids without the need for aggressive mechanical mixing. Crucially, this

unique physical structure perfectly replicates the exact organoleptic profile, mouthfeel, and taste of fresh, raw desert milk.

The strict implementation of LTSD guarantees that the naturally high concentrations of IgG, VHH nanobodies, native lactoferrin, and insulin-like peptides remain fully functional and biologically active. By immaculately preserving this raw nutritional and molecular profile, specialized manufacturers operating under rigorous, EU-certified LTSD protocols (as documented in the technical protocols of the CamelWay Research Division (Wadowski et al., 2026; camelway.eu) provide the highly reliable, therapeutic-grade dietary interventions required for successful, reproducible clinical applications in human gut health, systemic metabolic regulation, and pediatric neurodevelopmental support.

Critical Parameter	Low-Temperature Spray Drying (LTSD)	Traditional Freeze-Drying (Lyophilization)	Standard High-Heat Spray Drying
Bioactive Integrity (IgG & Lf)	>99% (Perfectly maintains native tertiary structure and binding efficacy)	~95% (High risk of structural cryodamage and vesicle rupture)	<40% (Severe, irreversible thermal denaturation of proteins)
Micro-Particle Morphology	Uniform, structurally closed microspheres	Irregular, highly porous and fractured flakes	Variable, often physically fractured or thermally burnt
Water Solubility Index	Instant, seamless reconstitution in ambient liquids	Slow, clumps heavily, requires vigorous mechanical agitation	Moderate to poor (characterized by high protein insolubility)
Industrial Flowability	Excellent (Free-flowing, low stress)	Poor (Highly sticky, cohesive, and prone to caking)	Good
Long-Term Organoleptic Profile	Clean, highly fresh raw milk taste	Often becomes chalky or noticeably oxidized over shelf life	Distinctly cooked, caramelized, or burnt notes

Restoration of the Intestinal Flora-SCFA-Mucosal Barrier Axis

Recent, highly sophisticated in vivo studies utilizing advanced metagenomic sequencing have provided profound, granular insights into precisely how intact camel milk functions as a powerful restorative agent for the severely damaged intestinal lining. A pivotal, exhaustive 2025 study (DOI: 10.3389/fmicb.2025.1723833) thoroughly investigated the differential preventive and therapeutic

effects of both raw camel milk (TC) and fermented camel milk (FTC) on Dextran Sulfate Sodium (DSS)-induced ulcerative colitis in controlled murine models.

Decisive Reversal of Pathological Colitis Manifestations

DSS-induced colitis models are the gold standard for replicating human Inflammatory Bowel Disease (IBD) because DSS chemically erodes the protective colonic mucin layer and directly targets the epithelial barrier, leading to extreme, rapid weight loss, physical colonic shortening, massive bloody diarrhea, and potentially fatal systemic toxemia. The 2025 investigation revealed that preemptive nutritional intervention with camel milk and fermented camel milk significantly, and rapidly, mitigated these devastating pathological hallmarks.

The treatment successfully prevented severe bodily wasting (with the FTC group maintaining an impressive 99% of their original baseline body weight, compared to a drop to 97% or lower in the untreated DSS control group) and drastically, significantly reduced the overall Disease Activity Index (DAI). Peak DAI scores were forcefully lowered from a severe 2.8 down to a mild 2.0 ($p < 0.01$). Furthermore, the gross physical deterioration and atrophy of the large intestine was successfully halted, with overall colon lengths preserved at a healthy 6.2 cm, compared to the severely shrunken 5.8 cm observed in the untreated diseased models ($p < 0.01$).

Sculpting and Reprogramming the Intestinal Flora

The core therapeutic mechanism driving this macroscopic physical healing is heavily rooted in the aggressive, targeted restoration of the gut microbiome architecture. The administration of DSS induces severe, chaotic dysbiosis, which is immediately marked by a highly elevated Bacteroidetes-to-Firmicutes ratio and the rapid, total collapse of protective, short-chain fatty acid-producing bacterial taxa. Exhaustive 16S rRNA gene sequencing demonstrated that camel milk administration aggressively and specifically counteracted this pathogenic dysbiosis.

Specific critical bacterial genera were heavily and beneficially modulated by the intervention:

- **Lachnospiraceae NK4A136 group:** This critical, highly beneficial bacterial family experienced a severe, catastrophic decline during the onset of the DSS-induced colitis. Preemptive camel milk intervention fully, robustly restored its relative abundance in the gut. *Lachnospiraceae* is absolutely integral to long-term gut health due to its prodigious, unique capacity to ferment complex dietary fibers into large volumes of butyrate. Its restored presence in the camel milk cohorts showed highly significant, direct positive correlations with preserved colon length and overall butyrate concentrations, and strong negative correlations with disease DAI scores and circulating levels of the inflammatory cytokine TNF-α.

- **Ruminococcaceae taxa:** Specific clades within this family responded dynamically to the treatment. *Ruminococcaceae* UCG-003 was heavily enriched by the milk and demonstrated a remarkable, mathematically significant positive correlation with the actual genetic expression of the tight junction protein occludin, thereby directly linking the presence of a specific microbe to the physical repair of the gut barrier. Conversely, potentially pathogenic taxa that traditionally enrich during severe inflammation, such as *Ruminococcaceae* UCG-010 (which is highly correlated with the pro-inflammatory marker IL-1β), were aggressively suppressed and outcompeted.

- **Lactobacillus and Bifidobacterium:** These essential, foundational lactic acid-producing bacteria, which were rapidly depleted during the severe onset of UC, were highly protected and significantly enriched. This effect was particularly pronounced in the cohorts receiving the fermented camel milk (FTC), further establishing the probiotic synergy of the fermented product.

The Short-Chain Fatty Acid (SCFA) Metabolic Engine

The direct, measurable biochemical consequence of restoring beneficial, fiber-degrading taxa like *Lachnospiraceae* is the exponential, highly beneficial increase in the production of Short-Chain Fatty Acids (SCFAs) in the colonic lumen. SCFAs, specifically acetate, propionate, and butyrate, act not only as the primary, indispensable metabolic fuel source for starving colonocytes but also function systemically as potent histone deacetylase (HDAC) inhibitors. By inhibiting HDAC, SCFAs actively

and epigenetically suppress the transcription of highly inflammatory genes within the host's intestinal cells.

The chemical DSS intervention caused a severe, highly significant drop ($p < 0.01$) in baseline acetic, propionic, and butyric acids, starving the colon of energy. However, the nutritional interventions with both standard camel milk (TC) and fermented camel milk (FTC) forcibly restored the metabolic machinery of the gut. This resulted in highly significant, life-saving increases in both acetic acid and propionic acid concentrations ($p < 0.05$) when directly compared to the starving, diseased controls. By actively fueling the exhausted epithelial cells and simultaneously downregulating localized, destructive inflammation, the SCFA axis completely enables the rapid, visible regeneration of the mucosal barrier.

Restoring the Physical Barrier and Re-establishing Immune Equilibrium

This profound microbial and metabolic optimization translates directly and measurably into physical, structural healing of the gut lining. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis - utilizing highly specific targeted primers (e.g., Forward: AACCTGAAGGCAGCCGACA for E-cadherin, and Forward: CCGTCTAATCAATCTTTGCAGC for Occludin) - revealed that camel milk treatments massively, significantly upregulated the genetic expression and physical presence of vital tight junction proteins. By chemically and physically sealing the broken paracellular spaces with newly synthesized occludin, ZO-1, and E-cadherin, the deadly leakage of endotoxins and LPS into the submucosa was successfully halted.

Immunologically, the camel milk interventions facilitated a rapid transition from a hyper-inflammatory, destructive state to a regulatory, healing one. This shift was biochemically characterized by the highly significant elevation of the potent anti-inflammatory cytokine IL-10 ($p < 0.05$). While both fresh and fermented camel milk exhibited profound, statistically significant protective traits across all markers, the fermented variant (FTC) demonstrated a superior, highly targeted efficacy in specifically preventing the critical loss of E-cadherin proteins and perfectly maintaining the crucial Bacteroidetes/Firmicutes baseline ratio.

Exosome-Mediated Colonic Repair and Microbiota-Metabolite Crosstalk

While macroscopic proteins like lactoferrin and IgG act powerfully within the open intestinal lumen, camel milk utilizes an entirely separate, highly advanced, and stealthy delivery system to enact profound epigenetic changes deep within the host's own cellular machinery: Extracellular Vesicles (EVs), commonly referred to as exosomes. Exosomes are incredibly resilient, nanosized lipid bilayer vesicles (ranging strictly from 30 to 200 nm in diameter) that encapsulate a dense, protected payload of bioactive microRNAs (miRNAs), messenger RNAs, and specialized signaling proteins. Because they are entirely encased in a highly durable lipid membrane, these exosomes easily and completely survive the highly acidic human gastric environment. Upon reaching the intestines, they are rapidly internalized by human intestinal epithelial cells, predominantly via clathrin-mediated endocytosis.

A landmark, comprehensive 2025 study (DOI: 10.3390/nu17152431) thoroughly explored the clinical application of Camel Milk-Derived Extracellular Vesicles (CM-EVs) in actively repairing severe colonic injury induced by acute hypobaric hypoxia. High-altitude hypobaric hypoxia acts as a severe, systemic stressor on the fragile GI tract, perfectly mimicking the massive oxidative stress, aggressive NF-κB-mediated inflammation, and deep mucosal erosion typically seen in severe Inflammatory Bowel Disease and late-stage "leaky gut" syndrome.

Complete Reversal of Hypoxic Colonic Injury

The targeted oral administration of isolated CM-EVs over a rigorous 15-day trial yielded extraordinary, statistically highly significant results, effectively and visibly outperforming the oral administration of whole, un-fractionated camel milk alone. The concentrated CM-EVs physically repaired the damaged mucosal architecture, completely restoring deep crypt integrity, halting epithelial apoptosis, and successfully reversing the severe villus blunting caused by the oxygen deprivation. This intense structural repair correlated directly with a highly significant decrease in the overall disease activity index ($p < 0.01$) and a substantial, measurable restoration of total colon length, proving macroscopic healing.

Microbiota-Metabolite Synergy and the Critical FXR/NF-κB Axis

The lead researchers of the study successfully identified a highly complex "synergistic microbiota-metabolite axis" that was entirely driven and orchestrated by the administration of the CM-EVs. The lipid vesicles aggressively reprogrammed the highly dysbiotic, hypoxia-damaged microbiome. They significantly and rapidly enriched key butyrate-producing genera, such as *Oscillospira* and *Ruminococcus*, while uniquely and selectively elevating the rare *AF12* genus, which the study identified as playing a novel, critical role in protecting fatty acid metabolism under extreme environmental stress.

This massive microbial restructuring resulted in profound, systemic metabolic reprogramming. The CM-EVs fully restored delicate bile acid homeostasis and completely optimized amino acid modulation pathways within the inflamed gut. Specifically, the treatment yielded unusually high, protective correlations of specific anti-inflammatory metabolites, notably **pantothenic acid** (which directly suppressed the dangerous differentiation of inflammatory Th17 cells) and **naringenin**.

At the deep molecular level, the CM-EVs exerted their systemic protective effects specifically through the modulation of the Farnesoid X Receptor (FXR) / NF-κB signaling pathway. The activation of the FXR receptor by the newly modulated, healthy bile acid pool directly and forcefully inhibited the inflammatory NF-κB transcription factor, while concurrently, drastically reducing TLR4/MyD88-mediated innate inflammation and cellular oxidative stress ($p < 0.01$). To absolutely prove therapeutic causality, the researchers performed highly complex Fecal Microbiota Transplantation (FMT) from the CM-EV-treated cohort directly into actively diseased recipient mice. The FMT procedure successfully and entirely replicated the barrier repair and profound anti-inflammatory effects in the recipients, definitively and scientifically proving that the CM-EVs heal the gut by fundamentally, permanently reprogramming the microbial and metabolic environment.

Epigenetic Regulation: The SIRT1/NF-κB Pathway and the Role of miR-148a-3p

To understand precisely *how* these camel milk exosomes (CME) manage to suppress such severe inflammation on a molecular level, a concurrent, highly detailed 2025 study (DOI: 10.1021/acs.jafc.5c11226) meticulously mapped the intracellular mechanics of CME and its specific microRNA cargo during the progression of DSS-induced colitis.

The Functional Dominance of Exosomal miR-148a-3p

Exosomes function as highly evolved, natural nanotherapeutics. The extensive research identified **miR-148a-3p** as a highly enriched, pivotal, and primary functional driver located within the core of camel milk exosomes. When the inflamed intestinal epithelial cells internalize the protective CME via endocytosis, this specific microRNA payload is physically released into the host cell's cytoplasm, where it immediately enacts direct, powerful gene regulation. The therapeutic, anti-inflammatory efficacy of isolated, purified miR-148a-3p was found to be statistically highly comparable to the administration of the entire, complex CME system, powerfully underscoring its precise role as the primary, active anti-inflammatory agent within the milk.

Upregulation of SIRT1 and Total Suppression of NF-κB

The primary, intended pharmacological target of the CME and its potent miR-148a-3p cargo is the highly conserved SIRT1/NF-κB signaling pathway. SIRT1 (Silent Information Regulator T1) is a crucial, universally recognized metabolic enzyme that acts as a powerful negative regulator of systemic inflammation. The oral administration of CME significantly, measurably upregulated the genetic expression and protein levels of SIRT1 within the heavily damaged colonic tissues of the diseased mice.

By successfully upregulating SIRT1, the resulting biochemical cascade aggressively and entirely inhibits the NF-κB pathway. The study accurately measured this inhibition via the precise ratio of phosphorylated p65 (p-p65) to total p65 - which is universally recognized as the primary molecular

indicator of NF-κB activation and subsequent inflammatory severity. DSS treatment alone drastically and dangerously elevated the p-p65/p65 ratio, driving severe, unchecked inflammation. However, treatment with CME and the targeted miR-148a-3p dramatically reduced this critical ratio, successfully sequestering the NF-κB molecules in the cytoplasm and entirely preventing the nuclear translocation absolutely required to transcribe tissue-destroying pro-inflammatory cytokines.

Macrophage Polarization and Barrier Upregulation

Beyond merely suppressing molecular inflammation cascades, the exosomal cargo actively dictates and alters the physical behavior of the host's innate immune system. The specific treatment actively and successfully promoted the rapid polarization of host macrophages, forcing them away from the highly inflammatory, tissue-damaging M1 phenotype (clearly marked by high levels of iNOS production) and toward the highly desirable, tissue-repairing M2 phenotype (marked by the strong expression of Arg1).

Remarkably, the isolated miR-148a-3p exhibited a highly potent, nearly total inhibitory effect on M1 iNOS expression, effectively extinguishing the primary cellular drivers of deadly oxidative damage within the delicate mucosa. Consequently, because the inflammatory assault was halted, the physical intestinal barrier was able to rapidly rescue and repair itself through the massive, unchecked upregulation of the tight junction protein ZO-1, successfully reversing the severe colon shortening and completely alleviating all visible clinical symptoms of the colitis.

Systemic Antioxidant Capacity and the Vital Gut-Liver Axis

Chronic, unmanaged intestinal inflammation invariably generates a massive, systemic storm of highly destructive Reactive Oxygen Species (ROS) that leak from the gut directly into the portal vein, subsequently severely compromising systemic health and heavily damaging hepatic (liver) function. A comprehensive 2025 metagenomic investigation (DOI: 10.3389/fcimb.2025.1621031) deeply evaluated the highly complex interplay between regular camel milk intake, resulting gut microbiota changes, and the host's overall systemic antioxidant capacity.

The detailed study definitively revealed that regular camel milk intervention actively, biochemically modulates the host animal's inherent capacity to neutralize dangerous free radicals across multiple organ systems. The highly significant enhancement of both liver and serum antioxidant indices was proven to be not merely a simple result of the innate, passive vitamins present in the milk (e.g., its naturally high Vitamin C content), but was fundamentally and biologically driven by the actively altered gut microbiota.

Specific, newly enriched microbial taxa in the camel milk cohorts were found to be significantly, mathematically correlated with massive increases in native antioxidant enzyme activities within the host's own organs. Deep metagenomic functional annotations clearly indicated that these rapid flora shifts optimize the host's fundamental metabolic and organismal systems, massively enhancing the systemic, natural clearance of highly destructive superoxide anions and peroxyl radicals from the blood. By completely resolving massive oxidative stress at the systemic level, camel milk prevents the deadly, cascading tissue damage that is highly characteristic of unchecked IBD, advanced leaky gut, and severe metabolic syndrome.

Molecular Pathway / Target	Precise Mechanism of Action by Camel Milk Bioactives	Direct Clinical / Physiological Outcome	Supporting Research Data
Bacteroidetes/ Firmicutes Ratio	Rapid reversal of dysbiosis; specific, targeted enrichment of Lachnospiraceae and Bifidobacterium taxa.	Massive increase in protective SCFA production (acetate, butyrate); total reduction in mucosal inflammation.	10.3389/ fmicb.2025.1723833
FXR/NF-κB Axis	CM-EVs totally reprogram microbial metabolic potential, restoring bile acid homeostasis to strongly activate FXR receptors.	Rapid, visible repair of hypoxia-induced colonic injury; total structural restoration of colonic crypts.	10.3390/nu17152431
SIRT1 Upregulation	Delivery of exosomal miR-148a-3p directly and rapidly upregulates SIRT1 gene expression in host epithelial cells.	Massive reduction of the p-p65/p65 ratio; complete silencing of NF-κB inflammatory cytokine transcription.	10.1021/ acs.jafc.5c11226
Macrophage Polarization	Epigenetic modulation via exosomes forcefully suppresses iNOS (M1 phenotype) and massively enhances Arg1 (M2 phenotype).	Halts the innate inflammatory assault; promotes highly active, rapid tissue regeneration and physical healing.	10.1021/ acs.jafc.5c11226
Tight Junction Proteins (TJPs)	Downstream suppression of inflammation allows for the massive, unchecked upregulation of ZO-1, occludin, and E-cadherin.	Complete physical sealing of the paracellular space; total resolution of "leaky gut" hyperpermeability.	10.3389/ fmicb.2025.1723833

Translational Clinical Nuances: Treating IBS, Leaky Gut, and Neurodevelopmental Disorders

The exhaustive, highly granular molecular data harvested from these advanced murine models of severe, chemically induced colitis presents a clear, undeniable, and highly actionable translational pathway for human functional nutrition. In highly prevalent conditions like Irritable Bowel Syndrome (IBS), the inflammation is frequently classified as "low-grade" rather than actively ulcerative; however, it is entirely characterized by the exact same underlying, destructive biological mechanisms: persistent

dysbiosis, chronic SCFA depletion, subtle but damaging barrier leaks, and a hyperactive, confused innate immune response.

The targeted, daily oral administration of preserved camel milk bioactives provides a massive, multi-dimensional intervention strategy for both IBS and chronic leaky gut syndrome. The naturally occurring nanobodies and high concentrations of lactoferrin perform immediate, localized pathogen clearance and provide a physical mucosal shield, while the resilient, lipid-bound exosomes effortlessly bypass gastric digestion to epigenetically reprogram the inflamed, damaged colonocytes from the inside out.

Furthermore, the rapid resolution of intestinal hyperpermeability achieved by camel milk has profound, highly documented implications for the emerging science of the "Gut-Brain Axis." When the gut is leaky, translocated bacterial endotoxins and un-digested, highly antigenic dietary proteins (such as powerful, opioid-like casomorphins derived from standard A1 bovine dairy) freely cross the compromised gut barrier into the systemic circulation. They subsequently breach the highly sensitive blood-brain barrier to trigger severe neuroinflammation and behavioral alterations.

As strongly highlighted by the ongoing, extensive clinical research frameworks and data repositories supervised by leading nutritional researchers, the strict application of pure A2, naturally casomorphin-free camel milk - crucially, only when processed via advanced, protein-sparing LTSD technology - serves as a highly critical, foundational complementary nutrition strategy. By rapidly repairing the physical tight junctions (ZO-1, occludin) via the action of exosomal miR-148a-3p and totally restoring the protective, butyrate-producing microbiome, intact camel milk effectively, physically halts the systemic translocation of these neurotoxic peptides into the brain. This precise, highly validated physical and biochemical mechanism strongly underpins the rapidly emerging, highly successful clinical evidence supporting the use of therapeutic-grade camel milk in strict dietary protocols for Autism Spectrum Disorders (ASD) and much broader neurodiversity support strategies.

Conclusion

The application of camel milk in modern gastroenterological therapeutics represents a highly sophisticated, breathtakingly complex interplay of microbiome ecology, precise epigenetic regulation, and highly advanced food engineering. Exhaustive, peer-reviewed clinical and multi-omic studies from 2024 and 2025 definitively confirm that camel milk actively prevents and rapidly repairs severe colonic injury, such as Ulcerative Colitis and intestinal hyperpermeability, through highly specific, scientifically validated mechanisms. These robust mechanisms include the total restoration of the gut microbiota-SCFA axis via the targeted enrichment of *Lachnospiraceae,* the powerful epigenetic suppression of the destructive NF-κB pathway via exosomal miR-148a-3p and subsequent SIRT1 upregulation, and the massive optimization of the host's systemic antioxidant capacity.

However, the vital transition of camel milk from a traditional, localized food source to a highly potent, globally available, clinical-grade nanotherapeutic is absolutely, undeniably dictated by industrial processing parameters. Conventional, high-heat pasteurization and standard freeze-drying fundamentally, irreversibly compromise the complex molecular architecture of the critical lactoferrin proteins, IgG antibodies, and delicate extracellular vesicles. Only through the precise, highly controlled application of Low-Temperature Spray Drying (LTSD) can these vital tertiary structures and fragile exosomal lipid bilayers be perfectly preserved in a shelf-stable, highly soluble, genuinely therapeutic-grade matrix. As clinical research pioneers and industry leaders continue to rigorously standardize these advanced, heat-sparing manufacturing protocols, the use of bio-identical, structurally intact camel milk powders offers an unprecedented, highly effective natural intervention for the long-term management of inflammatory bowel diseases, irritable bowel syndrome, and total systemic metabolic homeostasis.

References

Camel Milk, Gut Health & Microbiome

- Therapeutic Effects of Camel Milk Exosomes and Their miR-148a-3p Cargo on DSS-Induced Colitis: Modulating Gut Inflammation through the SIRT1/NF-κB Pathway and Microbiota Alterations
- Camel Milk-Derived Extracellular Vesicles as a Functional Food Component Ameliorate Hypobaric Hypoxia-Induced Colonic Injury Through Microbiota–Metabolite Crosstalk
- Camel milk and fermented camel milk prevent dextran sulfate sodium-induced ulcerative colitis
- Therapeutic effects of composite probiotics derived from fermented camel milk on metabolic dysregulation and intestinal barrier integrity in type 2 diabetes rats
- Changes in antioxidant capacity and gut microbiota in mice after intake of camel milk
- Fermented camel milk as a functional food for gut microbiota modulation: Mechanisms, therapeutic promise, and research gaps
- Gut Barrier Dysfunction and Microbiota Variations in Cryptosporidiosis: A Comprehensive Review
- Gut Microbial Dysbiosis in the Pathogenesis of Gastrointestinal Dysmotility and Metabolic Disorders
- Gut Microecological Prescription: A Novel Approach to Regulating Intestinal Micro-Ecological Balance
- Milk-derived extracellular vesicles and gut health
- Modulating the Gut Microbiome in Type 2 Diabetes: Nutritional and Therapeutic Strategies

Exosomes, Nanobodies & Advanced Therapeutics

- A new insight into the exosome protein and lipid composition in camel colostrum and mature milk using comparative proteome and lipidomics analyses
- Camel milk extracellular vesicles/exosomes: a fascinating frontier in isolation and therapeutic potential
- Camels' biological fluids contained nanobodies: promising avenue in cancer therapy
- Engineering a protease-stable, oral single-domain antibody to inhibit IL-23 signaling
- Small but Mighty: Nanobodies in the Fight Against Infectious Diseases
- Use of camel single-domain antibodies for the diagnosis and treatment of zoonotic diseases
- NANOBODY Molecule, a Giga Medical Tool in Nanodimensions

Nutritional Composition, Lactoferrin & General Benefits

- Camel milk: Nutritional composition, therapeutic properties, and benefits for human health

- Determination of Lactoferrin in Camel Milk by Ultrahigh-Performance Liquid Chromatography-Tandem Mass Spectrometry
- Lactoferrin: Properties and Potential Uses in the Food Industry
- Lactoferrin of camel milk of Kazakhstan
- The influence of heat treatment of lactoferrin powders on the physicochemical properties and bacteriostatic activity
- Nutritional, antimicrobial and medicinal properties of Camel's milk: A review
- Medicinal values of bioactive constituents of camel milk: A concise report
- Supplementation with Probiotic Camel Milk Powder Improves Serum Glucose and Cholesterol as Well as the Related Cytokines in Patients with Type 2 Diabetes Mellitus
- The Antioxidant, Anti-Inflammatory and Immunomodulatory Effects of Camel Milk
- Miraculous Properties of Camel Milk and Perspective of Modern Science
- Camel Milk and Diabetes: Science-Backed Benefits for Type 1 and Type 2 Patients
- Colostrum for Adults: Boosting Immunity Gut Health and Recovery

Spray Drying Technology & Stability

- Effects of low temperature spray drying conditions on physical properties of bovine colostrum powders
- Detailed Guide to Milk Powder Spray-Drying - Pilotech
- Functionality of milk protein concentrate: Effect of spray drying temperature
- The Impact of Atomization on the Surface Composition of Spray-dried Milk Droplets
- An Investigation and Quantitative Assessment of Particle Shape in Milk Powders from a Laboratory-Scale Spray Dryer
- Powdered plant beverages obtained by spray-drying without carrier addition - physicochemical and chemometric studies
- Freeze and Spray Drying Technologies to Produce Solid Microbial Formulations for Sustainable Agriculture
- Shelf life and storage stability of spray-dried bovine colostrum powders under different conditions
- Is it Possible to Produce Carrier-Free Fruit and Vegetable Powders by Spray Drying?

CamelWay Research & Resources

- Adrian Wadowski, Lead Researcher | Product Developer - CamelWay
- Spray Drying Technology | Soluble & Bioactive Camel Milk

- CamelWay™ Camel Milk Powder 300g
- Wholesale Camel Milk Powder: Premium B2B Supplier in Europe
- Camel Milk and the Gut-Brain Axis: Evidence-Based Support for Neurodiversity
- Relief for Eczema, Psoriasis & Acne: Camel Milk & Lactoferrin
- Camel Milk and Lactoferrin: The Bioactive Immune Shield and Gut Barrier Restoration

The author is affiliated with CamelWay, a producer of camel milk powder. However, this research is based on independently published, peer-reviewed studies (2024-2026) and aims to provide an objective synthesis of current clinical data.